Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetes
Preclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and cardiac profile relative to TZDs and dual PPARα/γ agonists

Daix (France), New York (New York, United States), September 8, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announces the presentation of five abstracts at the 12th Paris MASH Meeting taking place September 10-11, 2026, at the Pasteur Institut in Paris, France.

The abstracts present Phase 1 and Phase 2 clinical and preclinical data that further characterize the pan-PPAR pharmacological profile of lanifibranor and evaluate its potential effects on systemic metabolic dysfunction associated with MASH. Clinical data from Phase 1 and Phase 2 trials demonstrated direct PPAR target engagement, as reflected by increases in adiponectin, together with improvements observed in measures of insulin sensitivity, glycemic control, lipid parameters, and selected cardiovascular risk factors, with effects observed in patients with or without Type 2 diabetes. Separate preclinical studies demonstrated improvement in hepatic and metabolic parameters, and further characterized lanifibranor’s balanced pan-PPAR pharmacology, supporting a differentiated fluid and cardiac profile within the PPAR class.

Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis, with topline results expected in the fourth quarter of this year.

Following are the details of the poster presentations on September 10, 2026:

Abstract Title:	Beyond The Liver: Cardiovascular Effects of The Pan-PPAR Agonist Lanifibranor in Patients With MASH
Publication Number:	1256
Authors:	S. Francque, A. Holleboom, J. Campagna, S. Hogan, G. Wettstein, M. Abedelmalek
Abstract Title:	Metabolic Benefits of Pan-PPAR Agonist Lanifibranor in Patients With and Without Type 2 Diabetes
Publication Number:	1249
Authors:	A. Holleboom, M. Abdelmalek, S. Hogan, J. Campagna, G. Wettstein, S. Francque
Abstract Title:	Lanifibranor Improves Metabolic and Histological Features of MASH Across Multiple Preclinical Models: Convergent Pan-PPAR Activity
Publication Number:	1255
Authors:	A. Holleboom, S. Francque, J. Campagna, S. Hogan, G. Wettstein, M. Abedelmalek
Abstract Title:	Lanifibranor Phase 1/2A Experience – PPAR Engagement and Metabolic Activity Without Early Clinical Fluid Retention
Publication Number:	1254
Authors:	A. Holleboom, S. Hogan, J. Campagna, G. Wettstein, M. Abdelmalek, S. Franque
Abstract Title:	Partial PPAR Agonism Underlies Lanifibranor's Preclinical Fluid/Cardiovascular Safety Versus Full and Dual PPAR Agonists
Publication Number:	1344
Authors:	S. Francque, A. Holleboom, J. Campagna, S. Hogan, G. Wettstein, M. Abedelmalek

About Lanifibranor

Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor ("PPAR") isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and preclinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris ((ticker: IVA, OTC:IVEVF) and on the Nasdaq Global Market in the United States (ticker: IVA). https://www.inventivapharma.com

Contacts

Media Relations

Lisa Buffington: media@inventivapharma.com

Investor Relations

David Nikodem: IR@inventivapharma.com

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release are forward-looking statements. Some of these statements, forecasts, and estimates may be identified by the use of words such as, without limitation, "believe," "anticipate," "expect," "intend," "plan," "seek," "estimate," "may," "will," "could," "should," "designed," "hope," "target," "potential," "opportunity," "possible," "aim," and "continue" and other similar expressions. These statements are not historical facts, but rather statements of future expectations and other forward-looking statements based on management's beliefs. These statements reflect the opinions and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend on factors beyond Inventiva's control. There can be no guarantee, with respect to product candidates, that clinical trial results will be available on schedule, that future clinical trials will be initiated as planned, that product candidates will receive the necessary regulatory approvals, or that the milestones planned by Inventiva or its partners will be achieved on schedule, or even at all. Future results may differ materially from the anticipated future results, performance, or achievements expressed or implied by these statements, forecasts, and estimates due to a number of factors, including the fact that interim data or data from any interim analysis of ongoing clinical trials do not predict the future results of clinical trials, the fact that the DMC's recommendation does not prejudge any eventual marketing authorization, that Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on recruitment or the final impact on the results or timing of the NATiV3 trial or related regulatory issues, Inventiva is a clinical-stage company with no approved products and no historical revenue, Inventiva has incurred significant losses since its inception, Inventiva has never generated revenue from product sales, Inventiva will need additional capital to fund its operations, without which Inventiva may be required to significantly reduce its activities, delay or discontinue one or more of its research or development programs, expand its activities or capitalize on its business opportunities, and may not be able to continue as a going concern. Inventiva's ability to obtain financing and complete potential transactions on a timely basis, as well as whether, when, and to what extent dilutive instruments may be exercised and by which holders, Inventiva's future success depends on the successful clinical development, regulatory approvals, and subsequent commercialization of lanifibranor, preclinical studies or previous clinical trials are not necessarily predictive of future results, and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' claims regarding product candidates, Inventiva's expectations regarding its clinical trials may prove to be incorrect, and regulatory authorities may require additional stops and/or modifications to Inventiva's clinical trials. Inventiva's expectations regarding the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to implement its commercialization, marketing, and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with its existing partners or enter into new partnerships, and to fulfil its obligations under any agreements entered into in connection with such partnerships, the benefits of its current and future partnerships on the clinical development, regulatory approvals, and, if applicable, commercialization of its product candidates, as well as the achievement of milestones and timelines anticipated in connection with such partnerships, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of the applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, the recruitment and retention of patients in clinical trials is a costly and time-consuming process that could be made more difficult or impossible by multiple factors beyond the control of Inventiva and its partners, Inventiva's product candidates may cause adverse reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces significant competition, and Inventiva's activities, preclinical studies, and clinical development programs, as well as timelines, Inventiva's financial condition and results of operations could be materially and adversely affected by changes in laws and regulations, adverse conditions in its industry, geopolitical events, , epidemics, and macroeconomic conditions, including changes in international trade policies, global inflation, fluctuations in financial and credit markets, customs duties and other trade barriers, political unrest and natural disasters, uncertain financial markets, and disruptions in banking systems. In light of these risks and uncertainties, no representation is made as to the accuracy or completeness of these forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts, and estimates are only valid as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements.

Please refer to the Universal Registration Document for the fiscal year ended December 31, 20242025, filed with the Autorité des Marchés Financiers on April 8, 2025,and the Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (the "SEC") on April 8, 2026 for other risks and uncertainties affecting Inventiva, including those described under the heading "Risk Factors," and in future filings with the SEC. Other risks and uncertainties that Inventiva is not currently aware of may also affect its forward-looking statements and may cause actual results and timing of events to differ materially from those anticipated. All information contained in this press release is current as of the date of this release. Except as required by law, Inventiva has no intention or obligation to update or revise the forward-looking statements mentioned above. Therefore, Inventiva accepts no responsibility for the consequences arising from the use of any of the above statements.

Attachment

INVENTIVA Paris MASH Poster Presentations EN 9.8.26 1